¿Importa la secuencia de tratamiento en egfr +?: Factores que deberían ser considerados

20 / 33

• Analysis of PFS by BICR was consistent with the investigator-based analysis: HR 0.28 (95% CI 0.20, 0.38), p<0.001; median PFS 11.0 vs 4.2 months.
AURA3 primary endpoint: PFS by investigator assessment
Papadimitrakopoulou WCLC 2016; Published Mok et al. NEJM 2016